IV.1 Tamoxifen, a human carcinogen or the share of common risk factors?
- 1 August 1998
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 34, S43-S44
- https://doi.org/10.1016/s0959-8049(98)00107-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancerBritish Journal of Cancer, 1996
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Tamoxifen and menopausal status: risks and benefitsThe Lancet, 1996
- Endometrial Cancer following Breast CancerEpidemiology, 1996
- Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary MalignanciesJNCI Journal of the National Cancer Institute, 1995
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Long-Term Effects of Adjuvant Tamoxifen and/or Radiotherapy: The South Sweden Breast Cancer TrialActa Oncologica, 1992
- Carcinogenic Effects of Adjuvant Tamoxifen Treatment and Radiotherapy for Early Breast CancerActa Oncologica, 1992
- PELVIC IRRADIATION AND TAMOXIFEN AS RISK FACTORS FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988
- TAMOXIFEN AS RISK FACTOR FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988